Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 78 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control (Norepinephrine) Clear all
Completed Phase 2 Interventional Results available

eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk

NCT04437485
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Type 2 Diabetes, PreDiabetes, Insulin Resistance
Interventions
Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Active Control
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Sep 6, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional

Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

NCT06559306
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo, Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
84
States / cities
Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Decision Support for Intraoperative Low Blood Pressure

NCT02726620
View directory record Official record
Conditions
Hypotension
Interventions
Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
60 Years to 100 Years
Enrollment
22,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Sep 6, 2026, 1:35 AM EDT
Recruiting Phase 4 Interventional

A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

NCT06223880
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
AXS-05, Bupropion
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Bellflower, California • Lafayette, California • Oceanside, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Electrocardiographic (ECG) Safety Study of Droxidopa at Clinical and Supratherapeutic Dose

NCT01327066
View directory record Official record
Conditions
QTc Interval
Interventions
Droxidopa, Moxifloxacin, Placebo
Drug
Lead sponsor
Chelsea Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Long- Term Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01152554
View directory record Official record
Conditions
Major Depressive Disorder, MDD, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
93
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 6, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Exploring Sympathetic Nervous System Function in Individuals With Down Syndrome

NCT07238465
View directory record Official record
Conditions
Down Syndrome, Autonomic Dysfunction
Interventions
Fear Response, Cold Stress, Pain Response, Caffeine, 12-Hour Fast, Maximal Dynamic Exercise
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 6, 2026, 1:35 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Orthostatic Intolerance
Interventions
Droxidopa, Atenolol, Placebos
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder

NCT01153347
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
79
States / cities
Birmingham, Alabama • Tucson, Arizona • Conway, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 2Phase 3 Interventional

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

NCT01318434
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
EB-1010 25mg BID, SSRI Active, EB-1010 50mg BID, Placebo
Drug
Lead sponsor
Euthymics BioScience, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
43
States / cities
Arcadia, California • Beverly Hills, California • National City, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 6, 2026, 1:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Stress Hormones on Emotion and Cognition

NCT00032838
View directory record Official record
Conditions
Healthy
Interventions
Yohimbine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)

NCT01157078
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
37
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Results available

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

NCT01393782
View directory record Official record
Conditions
Septic Shock
Interventions
Angiotensin II
Drug
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Intravenous Norepinephrine for Orthostatic Hypotension

NCT01285908
View directory record Official record
Conditions
Orthostatic Hypertension
Interventions
Intravenous Norepinephrine Infusion
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Sep 6, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional

Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?

NCT01856127
View directory record Official record
Conditions
Sexual Dysfunction, Major Depressive Disorder
Interventions
Vilazodone, Sertraline
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 6, 2026, 1:35 AM EDT
Withdrawn Not applicable Interventional

Individualizing Antidepressant Treatment Using Pharmacogenomics and EHR-driven Clinical Decision Support

NCT03952494
View directory record Official record
Conditions
Depression
Interventions
Genomind®Professional PGx Express TM
Genetic
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 89 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Results available

A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication

NCT04937829
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
5 mg BI 1569912, 20 mg BI 1569912, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
10
States / cities
Garden Grove, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 6, 2026, 1:35 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Angiotensin II in Liver Transplantation

NCT04901169
View directory record Official record
Conditions
Liver Transplant; Complications, Vasoplegia
Interventions
Angiotensin II, Saline
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 4 Interventional

Relaxation Response Training for the Treatment of Rheumatoid Arthritis

NCT00056667
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Relaxation response and cognitive behavioral therapy, Relaxation response, RA education
Behavioral · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Sep 6, 2026, 1:35 AM EDT
Recruiting Not applicable Interventional

Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response

NCT04142177
View directory record Official record
Conditions
Chronic Low Back Pain
Interventions
Pain EASE, Tailored exercise, Continued Care and Active Monitoring, Cognitive Behavioral Therapy (CBT), Spinal Manipulation Therapy (SMT), Yoga
Other · Procedure · Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
2,529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Loma Linda, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 6, 2026, 1:35 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Study to Assess the Clinical Benefit and Safety of Droxidopa in Parkinson's Disease

NCT02066571
View directory record Official record
Conditions
Parkinson's Disease, Freezing of Gait, Cognitive Ability, General
Interventions
Droxidopa, sugar pill
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
2
States / cities
Chicago, Illinois • West Bloomfield, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Cerebrospinal Fluid Drainage (CSFD) in Acute Spinal Cord Injury

NCT02495545
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
CSFD and elevation of MAP, Maintenance of MAP
Procedure
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 6, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Long-Term Versus Short-Term Treatment of Generalized Anxiety Disorder With Venlafaxine XR

NCT00183274
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Venlafaxine XR, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 15, 2017 · Synced Sep 6, 2026, 1:35 AM EDT
Terminated Phase 4 Interventional

A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease

NCT03034564
View directory record Official record
Conditions
Parkinson Disease, Fatigue, Parkinsonism
Interventions
Northera, Placebo Oral Tablet
Drug
Lead sponsor
The Cooper Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 22, 2021 · Synced Sep 6, 2026, 1:35 AM EDT